| REL-1017 (esmethadone; d-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats J Henningfield, D Gauvin, F Bifari, R Fant, M Shram, A Buchhalter, ... Scientific Reports 12 (1), 11389, 2022 | 10 | 2022 |
| No meaningful opioid abuse liability of REL-1017 (esmethadone; d-methadone), a rapid-acting antidepressant in clinical development: a human abuse potential study J Henningfield, G Apseloff, C Gorodetsky, M Pappagallo, M Shram, ... Neuropsychopharmacology 46 (SUPPL 1), 241-242, 2021 | 2 | 2021 |
| Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder B Robertson, J Wu, RV Fant, SH Schnoll, SL McElroy The Primary Care Companion for CNS Disorders 22 (2), 23818, 2020 | 1 | 2020 |
| Risk of death associated with kratom use compared to opioids JE Henningfield, O Grundmann, JK Babin, RV Fant, DW Wang, EJ Cone Preventive medicine 128, 105851, 2019 | 42 | 2019 |
| 4.3 EFFECTS OF ABUSED DRUGS ON PUPILLARY SIZE AND THE LIGHT REFLEX WB PICKWORTH, RV FANT, EB BUNKER Drug abuse handbook, 266, 2019 | 12 | 2019 |
| Behavioral economic demand metrics for abuse deterrent and abuse potential quantification LP Schwartz, PG Roma, JE Henningfield, SR Hursh, EJ Cone, ... Drug and Alcohol Dependence 198, 13-20, 2019 | 22 | 2019 |
| Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum MF Stiles, LR Campbell, T Jin, DW Graff, RV Fant, JE Henningfield Psychopharmacology 235, 2077-2086, 2018 | 27 | 2018 |
| The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research JE Henningfield, RV Fant, DW Wang Psychopharmacology 235, 573-589, 2018 | 150 | 2018 |
| Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability MF Stiles, LR Campbell, DW Graff, BA Jones, RV Fant, JE Henningfield Psychopharmacology 234, 2643-2655, 2017 | 58 | 2017 |
| Eluxadoline demonstrates a lack of abuse potential in phase 2 and 3 studies of patients with irritable bowel syndrome with diarrhea RV Fant, JE Henningfield, BD Cash, LS Dove, PS Covington Clinical Gastroenterology and Hepatology 15 (7), 1021-1029. e6, 2017 | 25 | 2017 |
| An Assessment of Camel Snus Abuse Liability JE Henningfield, RV Fant, BA Kleykamp | | 2017 |
| Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea Short title: Abuse potential of eluxadoline RV Fant, JE Henningfield, BD Cash, LS Dove, PS Covington | | 2017 |
| Assessment of the abuse potential and benefits of Kratom and its Mitragynine alkaloids: implications for regulation RK Lanier, RV Fant, E Cone, J Henningfield Drug and Alcohol Dependence 100 (171), e114, 2017 | 4 | 2017 |
| Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research JE Henningfield, TT Smith, BA Kleykamp, RV Fant, EC Donny Psychopharmacology 233, 3829-3848, 2016 | 17 | 2016 |
| Behavioral pharmacology contributions to regulation of drug and tobacco products by the Food and Drug Administration. JE Henningfield, AR Buchhalter, RV Fant Behavior Analysis: Research and Practice 16 (4), 179, 2016 | 8 | 2016 |
| Mo1309 Lack of Abuse Potential of Eluxadoline: Data From Phase 2 and 3 Studies RV Fant, JE Henningfield, BD Cash, LS Dove, PS Covington Gastroenterology 150 (4), S693-S694, 2016 | | 2016 |
| Perampanel Discontinuation Is Not Associated With Self-Reported Withdrawal Symptoms in Patients Completing Phase III Clinical Studies (P1. 232) M Rogawski, H Yang, R Fant, B Williams, D Xing, C Dobrinsky, ... Neurology 84 (14_supplement), P1. 232, 2015 | 1 | 2015 |
| Risk Management Implications of Abuse Potential Assessment JE Henningfield, AR Buchhalter, EJ Cone, MD Ertischek, RV Fant, ... Nonclinical Assessment of Abuse Potential for New Pharmaceuticals, 269-287, 2015 | | 2015 |
| Evaluation of electronic nicotine delivery systems: Regulatory precedents from the FDA 2013 draft guidance for abuse-deterrent opioids J Henningfield, EJ Cone, AR Buchhalter, RV Fant, JG Gitchell, JM Pinney Drug and Alcohol Dependence 100 (156), e94-e95, 2015 | 2 | 2015 |
| Abuse potential assessment of novel opioid analgesic NKTR-181: Implications for labeling and scheduling LR Webster, S Smith, J Silowsky, K Gogas, A Odinecs, M Eldon, N Abrouk, ... Drug and Alcohol Dependence, e239, 2014 | 4 | 2014 |
